The dual potential of topical roflumilast: advancing psoriasis therapy and pioneering oral mucosal disease treatment.

The shared pathophysiology between psoriasis and recurrent aphthous ulcers provides a strong rationale for repurposing PDE4 inhibitors across these conditions. This review advocates for accelerated translational efforts to evaluate topical roflumilast specifically for oral ulcer management and to broaden its therapeutic application across other chronic inflammatory diseases guided by precision immunomodulation principles.